Global Chemotherapy Induced Nausea & Vomiting (CINV) Market: Size, Trends & Forecasts (2016-2020)

DELHI, India - Oct. 3, 2016 - PRLog -- key opportunities in the market and outlines the factors that are and will be driving the growth of the industry. Growth of the overall global CINV market has also been forecasted for the period 2016-2020, taking into consideration the previous growth patterns, the growth drivers and the current and future trends.

The competition in global CINV market is fragmented as the specific treatment for CINV is still at a nascent stage with several drugs by multiple competitors already thriving the market and some are under formulation.

The key players of the global CINV market, Heron Therapeutics, Inc., Merck & Co., Inc., Novartis AG and TESARO, Inc. are also profiled with their financial information and respective business strategies

Country Coverage

North America

Company Coverage

Heron Therapeutics, Inc.
Merck & Co., Inc.
Novartis AG
TESARO, Inc.

Executive Summary

Chemotherapy induced nausea and vomiting (CINV) is the most dreaded side-effect of chemotherapy among the cancer patients. Therefore, sometimes patients either do not undergo the chemotherapy or discontinue in the prior year of treatment. CINV is also of various types such as acute, breakthrough, delayed, anticipatory and refractory. HEC and MEC regimens cause the CINV. Several treatments of CINV are on the verge of emergence such as 5-HT3 receptor antagonist, NK-1 blocker, corticosteroids, cannabinoids and dopamine antagonists. However, there are several unmet medical needs in the field of HEC regimen of delayed CINV.

Global CINV market has increased at a significant CAGR during the years 2013-2015 and projections are made that the market would rise tremendously in the next four years i.e. 2016-2020. The CINV market is expected to increase due to growth in global cancer incidence, increasing health expenditure and the increasing outbreak of factors working towards causing cancer. Yet, the market faces some challenges such as discontinuation of chemotherapy treatment, several unmet medical needs, no drugs for the HEC regimen in the delayed CINV, etc.

List of Figures:

Figure 1: Side-Effects of Chemotherapy

Figure 2: Delivery Methods of Chemotherapy

Figure 3: Types of Chemotherapy Drugs

Figure 4: Pros & Cons of Chemotherapy

Figure 5: Types of CINV

Figure 6: CINV Mechanism

Figure 7: Regimens Causing CINV

Figure 8: Treatment/Prevention of CINV

Figure 9: Global CINV Market Opportunity; 2015

Figure 10: Global CINV Market by Value; 2013-2015 (US$ Billion)

Figure 11: Global CINV Market by Value; 2016-2020 (US$ Billion)

Figure 12: Global VARUBI Sales; 2016-2020 (US$ Million)

Figure 13: Global Emend (Injectable) Sales; 2009-2015 (Thousand)

Figure 14: Global Aloxi (Injectable) Sales; 2009-2015 (Million)

Figure 15: Global Granisetron Sales; 2009-2015 (Thousand)

Figure 16: Global Ondansetron Sales; 2009-2015 (Million)

Figure 17: North America CINV Market by Value; 2013-2015 (US$ Million)

Figure 18: North America CINV Market by Value; 2016-2020 (US$ Million)

Figure 19: US CINV Market Opportunity; 2015

Figure 20: US CINV Market by Drugs Prescription; 2015 (Million)

Figure 21: US 5-HT3 Drug Prescription by Segments; 2015

Figure 22: Global Incidence of Cancer; 2012-2019 (Million)

Figure 23: Causes of Cancer; 2014

Figure 24: Global Healthcare Expenditure; 2009-2014 (US$ Trillion)

Figure 25: Unmet Needs in Prevention of CINV

Figure 26: Discontinuation of Chemotherapy Treatment

Figure 27: Breakthrough CINV by Regimen; 2015 (Percentage, %)

Figure 28: Breakthrough CINV by Occurrence; 2015

Figure 29: Heron Net Loss; 2011-2015 (US$ Billion)

Figure 30: Heron Research & Development Expenditure; 2011-2015 (US$ Million)

Figure 31: Merck & Co., Inc. Sales; 2011-2015 (US$ Billion)

Figure 32: Merck & Co., Inc. Sales by Segments; 2015

Figure 33: Novartis AG Business Segments

Figure 34: Novartis AG Total Sales; 2011-2015 (US$ Billion)

Figure 35: Novartis AG Sales by Segments; 2015

Figure 36: TESARO, Inc. Net Loss; 2011-2015 (US$ Million)

Figure 37: TESARO, Inc. Research & Development Expenditure; 2011-2015 (US$ Million)

Table 1 : Regimens Causing CINV

Table 2: Drugs for CINV

Table 3: Side-Effects of Chemotherapy

Table 4: CINV Market Players by Agents Approved and In Development

Table 5: Comparison of NK1 Receptor Antagonists

For further details, kindly visit :

http://www.daedal-research.com//global-chemotherapy-induced-nausea-vomiting-cinv-market-size-trends-forecasts-2016-2020 (http://www.daedal-research.com/global-chemotherapy-induce...)

Rajeev Kumar

(Business Development Manager)

Address:  36 SFS Flats

Paschim Vihar

New Delhi-110063

Mobile: +91-8743975789

Tel: +91-120-4553017

Mail ID - info@daedal-research.com

Daedal Research is a research and consulting firm specialized in providing research reports and customized business research and analysis. For more Information:

http://www.daedal-research.com